Landscapes / Companies
Iovance Biotherapeutics, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
4
in active trials · 9 in all
Trials
8 active
14 since 2021
Drugs4
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Cell therapy |
Approved | Dec 2027Phase 2 trial completes | |||
| How it works | A cell therapy | ||||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Metastatic Melanoma, Unresectable Melanoma and 9 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Sep 2027Phase 1/2 trial completes | |||
| Next date | Sep 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Unresectable Melanoma, Metastatic Melanoma and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Jun 2032Phase 1/2 trial completes | |||
| Next date | Jun 2032 · Phase 1/2 trial completes | ||||
| Also tested for | Unresectable Melanoma, Metastatic Melanoma and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Mar 2034Phase 1/2 trial completes | |||
| Next date | Mar 2034 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Non-Small Cell Lung Cancer and 5 more | ||||
| Open drug page | |||||
About
- No active trial
- IL-2, IOV-2001, LN-145-S1, LN-145/LN-144, Nivolumab-relatlimab
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021